ClinicalTrials.gg
RecruitingNCT07252895EXO-MOBILITYUpdated Apr 6, 2026

EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis

An interventional study of EXOPULSE Suit in Active mode and EXOPULSE Suit in Sham mode in Multiple Sclerosis, sponsored by Otto Bock France SNC. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Otto Bock France SNC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.

Planned enrollment
162nd of 244
77 · median 144
Started
2026
with 12 others
No phase
110 of 376
32 open now
Primary completion
2027-03
later than 43 of 91 live
Registered
365th of 376
by date

Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 162nd largest by planned enrollment of the 244 interventional ones that give a count, is one of 13 that started in 2026, is one of 110 with no phase, reaches primary completion later than 43 of the 91 other live ones, and was the 365th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Multiple Sclerosis with a site in France, or all of them as a file.
02

Study summary

The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.

This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis, including improvements in walking ability.

Read the detailed description

Lower limb function is perceived as essential by individuals with multiple sclerosis. The loss of walking ability is a major physical manifestation among individuals with an EDSS score between 4 and 7 and negatively impacts activities of daily living and employment. Various therapeutic options can be proposed to maintain or improve mobility, such as rehabilitation-which is an essential and irreplaceable component of the clinical care pathway-or treatments aimed at reducing symptoms such as spasticity, fatigue, or pain.

Fampridine is the only treatment exclusively intended to improve walking ability. However, not all individuals can benefit from this medication due to contraindications, side effects, lack of response, or loss of response over time. Some individuals also prefer to avoid drug-based treatments.

The EXOPULSE Suit is a class IIa-certified electrical medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day.

The EXOPULSE Suit may represent an alternative for improving walking ability in individuals who cannot be treated with Fampridine.

This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis and to demonstrate improved walking ability with the EXOPULSE Suit compared with a sham condition.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • neuromodulation
  • suit
  • walking ability
  • multi-site electrical stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Person with a clear Multiple Sclerosis diagnosis according to the 2017 revision of the McDonald criteria since at least 3 months.
  • Person with an Expanded Disability Status Scale (EDSS) score ≥ 4 and ≤ 6
  • Person with stable walking ability for at least two weeks prior to the inclusion visit (variation at the MSWS-12 questionnaire \< 8/100 points)
  • Person not treated with fampridine due to or adverse events or not respondent or no longer respondent or reluctant to taking drugs
  • Person with spasticity at the lower limb(s), attested by a Modified Ashworth Scale ≥ 1+ of at least one of the following muscle groups: quadriceps, hamstrings, triceps surae, tibialis anterior
  • Person who never tried EXOPULSE SUIT

Exclusion criteria

Exclusion Criteria:

  • Person under 18 years old
  • Person having a to using EXOPULSE SUIT
  • Person using an electronic life-support equipment, e.g. pacemakers or hight-frequency surgical equipment and person using an equipment
  • Person affected by other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
  • Person with relapses over the last 3 months before the inclusion
  • Person who had a modification of his/her medical treatments of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion
  • Person who had a new medical treatment of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion
  • Person who had an injection of botulinum toxin in at least one of the main muscle groups of the lower limbs over the last 4 months before the inclusion
  • Person planning to use a new medical device during the study (ex: ankle-foot orthosis…)
  • Person undergoing or planning to undergo an intensive rehabilitation phase
  • Person that is part of another study
  • Person who cannot be fitted with EXOPULSE SUIT due to inexistent Suitable size of the Suit (eg: >35; user height \< 100 cm or > 205cm)
  • Person who does not have a smartphone or who cannot or does not want to use his/her smartphone for operating the EXOPULSE App
  • Person not available to undergo all medical visits during the study
  • Person unable to understand verbal and written instructions in french
  • Pregnant person
  • Persons under juridical protection
  • Prisoners
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
77 participants (estimated)

Study arms

  • Other
    EXOPULSE Suit Active then EXOPUSLE Suit sham

    The participant is fist using the EXOPULSE Suit in Active mode for 4 weeks, then he has a 4-weeks wash-out period, then he is using the EXOPULSE Suit in a sham mode for 4 weeks.

    Device: EXOPULSE Suit in Active mode · Device: EXOPULSE Suit in Sham mode

  • Other
    EXOPULSE Suit in sham mode then EXOPULSE Suit in Active mode

    The participant is first using the EXOPUISE Suit in sham mode for 4 weeks, then he has a 4-weeks wash-out phase, the he is using the EXOPULSE Suit in Active mode for 4 weeks.

    Device: EXOPULSE Suit in Active mode · Device: EXOPULSE Suit in Sham mode

Interventions

  • DeviceEXOPULSE Suit in Active mode

    The EXOPULSE Suit in Active mode stimulates the targeted muscles during the whole 60-minutes cession

  • DeviceEXOPULSE Suit in Sham mode

    The EXOPULSE Suit in Sham mode stimulates the targeted muscles during the first minute of the cession then is off during the 59 minutes left.

06

What researchers measure

Primary outcomes

  1. The Multiple Sclerosis Walking Scale 12 (MSWS-12)

    The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a 12-item assessment tool designed to measure the impact of multiple sclerosis (MS) symptoms on patients' walking and balance ability, through a series of questions about various daily activities performed over the previous two weeks. Patients are asked to rate the impact of MS on their mobility using a five-point Likert scale, ranging from 1, indicating "no im-pact", to 5, meaning "extremely significant impact". The final score is obtained by adding the responses to the 12 questions (with a sum ranging from 12 to 60). This sum is then converted to a scale of 0 to 100, where a higher score reflects a greater impact of symptoms on the patient's walking ability.

    Time frame: 28 days

Secondary outcomes

  1. 10 Meters Walk Test (10MWT)

    The 10MWT is a performance measure that assesses walking speed in meters per second over a short dis-tance. A high score indicates a fast-walking speed. At a comfortable speed, the patient is asked to walk over 10 meters, plus 2 meters at the beginning and at the end for acceleration and deceleration.

    Time frame: 28 days

  2. 2-minute Walk Test (2MWT)

    The 2-minute Walk test is a measurement of endurance that assesses the maximum walking distance over 2 minutes. A long walking distance reflects good endurance.

    Time frame: 28 days

  3. Timed-up and go Test (TUG)

    The Timed Up and Go (TUG) test is a validated tool in people with MS to assess functional mobility. It measures the time it takes a person to get up from a chair (without the help of the hands), walk 3 meters, turn around a cone / mark on the floor, return to the chair, and sit back down. Patients are instructed to complete the course as safely and quickly as possible. If needed, patients are allowed to use assistive devices while performing the task. They are given 2 trials to complete the TUG test and the computed time across the 2 trials is the final score. A high value reflects an increased risk of falling.

    Time frame: 28 days

  4. Visual Analog Scale - Fatigue (VAS - Fatigue)

    The VAS is a measurement tool where the patient rates his fatigue level by marking a point on a 10 cm line that represents a continuum between "no fatigue" and "worst possible fatigue". The measurement (in mm) between the left end of the line and the mark done by the patient represents the level of fatigue perceived by the patient. The score is then expressed by a note between 0 and 10, 10 being the worst pos-sible fatigue.

    Time frame: 28 days

  5. The Modified Ashworth Scale (MAS)

    The Modified Ashworth Scale (MAS) is a revised version of the original Ashworth Scale that measures spasticity in patients with lesions to the central nervous system. MAS measures the increase in muscle tone by assigning a grade of spasticity from 0 to 4. The grade is assigned by moving a joint/muscle through a high velocity quick stretch. MAS grades: 0 : No increase in muscle tone 1 : Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ : Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement) 2 : More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved 3 : Considerable increase in muscle tone passive, movement difficult 4 : Affected part(s) rigid in flexion or extension

    Time frame: 28 days

  6. The Multiple Sclerosis Impact Scale 29-items (MSIS-29)

    The Multiple Sclerosis Impact Scale 29-items (MSIS-29) is 29-items' self-questionnaires that measure the physical and psychological impact of MS on day-to-day life in the past two weeks. . It comprises 20 items associated with a physical scale and a 9-items scale with a psychological scale. Each item has 5 response options going from 1 "not at all" to 5 "extremely". Each of the two scales are scored by summing the response across items, then converting to a 0-100 scale where 100 indicates a greater impact of disease on daily function. The physical impact score is computed by summing items number 1-20 inclusive. This score can then be transformed to a score on a scale of 0 -100 using this formula: (100\*(observed score-20))/(100-20). The psychological impact score is computed by summing items number 21-29 inclusive. This score can then be transformed to a score on a scale of 0 -100 using this formula: (100\*(observed score-9)/(45-9).

    Time frame: 28 days

  7. The EuroQol - 5 Dimensions -5 levels (EQ-5D-5L)

    The EuroQol - 5 Dimensions -5 levels (EQ-5D-5L) is a scale developed by the EuroQol group that assesses quality of life through 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxie-ty/depression. Each dimension has 5 levels going from "no problems" to "extreme problems". Health status can be defined by an index value that goes between 0 and 1. It expresses how is the health status, according to preferences of the general population of a given country. Health status is also expressed by the EQ VAS (Visual Analogue Scale). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labeled 'The best health you can imagine' and 'The worst health you can imagine'. VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgment.

    Time frame: 28 days

  8. Visual Analog Scale - Pain (VAS - Pain)

    The VAS is a measurement tool where the patient rates his perceived general pain level by marking a point on a 10 cm line that represents a continuum between "no pain" and "worst possible pain". The measurement (in mm) between the left end of the line and the mark done by the patient represents the level of pain perceived by the patient. The score is then expressed by a note between 0 and 10, 10 being the worst possible pain.

    Time frame: 28 days

Other outcomes

  1. Feeling during the stimulation

    4 additional questions related to the feeling during the stimulation will be asked: pain, tingling, burning, fatigue. Data considered are with EXOPULSE Suit in active mode.

    Time frame: 28 days

  2. Satisfaction with the suit

    4 additional questions related to the satisfaction with the suit will be asked: ease for putting on and off, ease of use, comfort with the suit, efficacy. Data considered are with EXOPULSE Suit in active mode.

    Time frame: 28 days

07

Study locations

9 of 11 sites recruiting
  • Centre Jacques Calvé Fondation Hopale
    Berck, 62 608, France
    Recruiting
    • Pascal RIGAUX, Dr. · Contact
    • Pascal RIGAUX, Dr. · Principal investigator
  • CHU Henri Mondor
    Créteil, 94000, France
    Recruiting
    • Samar AYACHE, Pr. · Contact
    • Samar AYACHE, Pr. · Principal investigator
  • CHU Dijon
    Dijon, 21 079, France
    Recruiting
    • Paul ORNETTI, Pr. · Contact
    • Paul ORNETTI, Pr. · Principal investigator
  • Clinique Verdaich
    Gaillac-Toulza, 31 550, France
    Recruiting
    • Elsa MAURUC-SOUBIRAC, Dr. · Contact
    • Elsa MAURUC-SOUBIRAC, Dr. · Principal investigator
  • Hôpital Raymond-Poincaré
    Garches, 92380, France
    Recruiting
    • Djamel BENSMAIL, Pr. · Contact
    • Djamel BENSMAIL, Pr. · Principal investigator
    • Nicolas ROCHE, Dr. · Sub investigator
    • Jonathan LEVY, Dr. · Sub investigator
  • Hopital Saint Philibert
    Lomme, 59462, France
    Active, not recruiting

    Not enrolling at this site.

  • Centre Médical Germaine REVEL
    Lyon, 69 440, France
    Recruiting
    • Vivien RAYNAUD, Dr. · Contact
    • Vivien RAYNAUD, Dr. · Principal investigator
  • Hôpital L'Archet
    Nice, 62 000, France
    Not yet recruiting
    • Audrey ALLAMANDI, Dr. · Contact
    • Audrey ALLAMANDI, Dr. · Principal investigator
  • Pole MPR Saint Hélier
    Rennes, 35000, France
    Recruiting
    • Philippe GALLIEN, Dr. · Contact
    • Philippe GALLIEN, Dr. · Principal investigator
  • Hôpital Henry Gabrielle
    Saint-Genis-Laval, 69 230, France
    Recruiting
    • Sophie JACQUIN COURTOIS, Dr. · Contact
    • Sophie JACQUIN COURTOIS, Dr. · Principal investigator
  • Hôpital de Hautepierre
    Strasbourg, 67200, France
    Recruiting
    • Jérôme DE SEZE, Pr. · Contact
    • Jérôme DE SEZE, Pr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252895
Lead sponsor
Otto Bock France SNC
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Mar 30, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Aurelie LACROIX, Ing.
Contact
aurelie.lacroix@ottobock.com
0033 (0)7 86 29 52 03
Samar AYACHE, Pr
study chair · CHU Henri Mondor
Djamel BENSMAIL, Pr
study chair · Hôpital Raymond Poincaré
Jérôme DE SEZE, Pr
study chair · Hôpital de Hautepierre
Volker LIMMROTH, Pr
study chair · Klinik für Neurologie Köln-Merheim

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion